Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

NCT06374602 is registered in ClinicalTrials.gov with Saint Petersburg State University, Russia as lead sponsor.

NCT NCT06374602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06374602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Lead sponsor
Saint Petersburg State University, Russia
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2024
Completion date
June 25, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer